Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Nivolumab 2pembrolizumab 1osimertinib 1icotinib 1famitinib 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Pemetrexed 1Panitumumab 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Injections 1Immune Checkpoint Inhibitors 1Gefitinib 1Eflornithine 1Drug Therapy 1Cisplatin 1Celecoxib 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carcinoma, Non-Small-Cell Lung × Biological Assay × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡